5-PAHSA
Based on 1 Customer Validation
5-PAHSA increases insulin sensitivity, and has orally active anti-inflammatory and neuroprotective effects in mice HFD-induced diabetes mice. 5-PAHSA can be used for research of neurological dysfunction in diabetics.
For research use only. We do not sell to patients.
- Purity : 99.97%
- CAS No.: 1481636-41-2
- Formula: C34H66O4
- Molecular Weight:538.89
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-117586
9-PAHPAAntidiabetic/Anti-inflammatory Agent -
HY-158584
13-OAHSAFAHFA -
HY-W709961
5-OAHSAEndogenous Metabolite -
HY-131668
9-POHSAAnti-Inflammatory Agent -
HY-138177
Butyryl-Coenzyme A sodiumButyric Acid Derivative -
HY-113878
12-OAHSAAnti-Obese Agent -
HY-158583
13-POHSAFAHFA -
HY-131934
9-OAHSAAnti-Inflammatory reagent -
HY-130434
12-SAHSAFAHFA -
HY-116193R
5-PAHSA (Standard)Anti-Inflammatory Agent -
HY-130352
9-SAHSAFAHFA -
HY-133851
10-PAHSAFatty Ester
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
In Vitro
5-PAHSA (30 μM, 12 h) reduces the levels of ROS and induces autophagy in PC12 cells[1].
5-PAHSA (20 μM, 2 days) reduces high insulin- and TNF-α-induced insulin resistance in HepG2 cells and 3T3-L1 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
5-PAHSA (45 mg/kg, oral gavage, 3 days) stimulates De novo lipogenesis and lipid remodeling in epididymal WAT (eWAT) during cold exposure in mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1481636-41-2
-
Appearance Solid
-
Molecular Weight 538.89
-
Formula C34H66O4
-
Color White to off-white
-
SMILES
OC(CCCC(CCCCCCCCCCCCC)OC(CCCCCCCCCCCCCCC)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 16.67 mg/mL (30.93 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.67 mg/mL (3.10 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 1.67 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (647 KB)
- English - EN (647 KB)
- Français - FR (647 KB)
- Deutsch - DE (647 KB)
- Norwegian - NO (647 KB)
- Español - ES (647 KB)
- Swedish - SV (647 KB)
- Italian - IT (647 KB)
- Korean - KR (647 KB)
- Portuguese - PT (647 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang JT, et al. A novel palmitic acid hydroxy stearic acid (5-PAHSA) plays a neuroprotective role by inhibiting phosphorylation of the m-TOR-ULK1 pathway and regulating autophagy. CNS Neurosci Ther. 2021 Apr;27(4):484-496. [Content Brief]
[2]. Paluchova V, et al. Lipokine 5-PAHSA Is Regulated by Adipose Triglyceride Lipase and Primes Adipocytes for De Novo Lipogenesis in Mice. Diabetes. 2020 Mar;69(3):300-312. [Content Brief]
[3]. Wang YM, et al. High Glucose Concentration Impairs 5-PAHSA Activity by Inhibiting AMP-Activated Protein Kinase Activation and Promoting Nuclear Factor-Kappa-B-Mediated Inflammation. Front Pharmacol. 2019 Jan 7;9:1491. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8557 mL | 9.2783 mL | 18.5567 mL | 46.3917 mL |
| 5 mM | 0.3711 mL | 1.8557 mL | 3.7113 mL | 9.2783 mL | |
| 10 mM | 0.1856 mL | 0.9278 mL | 1.8557 mL | 4.6392 mL | |
| 15 mM | 0.1237 mL | 0.6186 mL | 1.2371 mL | 3.0928 mL | |
| 20 mM | 0.0928 mL | 0.4639 mL | 0.9278 mL | 2.3196 mL | |
| 25 mM | 0.0742 mL | 0.3711 mL | 0.7423 mL | 1.8557 mL | |
| 30 mM | 0.0619 mL | 0.3093 mL | 0.6186 mL | 1.5464 mL |
5-PAHSA Related Classifications
HY-116193 Related Classifications
Powered by Bioz